You are seeing these quotes based on previous browsing related to sectors such as
Latest | Forecast | |
---|---|---|
Div Yield | 0.0% | 0.0% |
Div Cover | n/a | n/a |
Op Mrgn | 0.0% | n/a |
ROCE | 0.0% |
Latest | Forecast | |
---|---|---|
P/E | -5.6 | 0.0 |
PEG | 0.0 | -999,999.0 |
Price / Revenue | 0.0 | 0.0 |
Price / Book value | 5.2 |
Latest | Forecast | |
---|---|---|
Revenue | n/a | 0.0% |
PBT | 0.0% | n/a |
EPS | 0.0% | 19.7% |
DPS | n/a | 0.0% |
Year Ending | Revenue (£m) |
Pre-tax (£m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
---|---|---|---|---|---|---|---|---|
2018-04-30 | n/a | -4.94 | -1.31p | -9.1 | 0.0 | n/a | n/a | 0.0% |
2019-04-30 | n/a | -6.71 | -1.42p | -3.6 | 0.0 | n/a | n/a | 0.0% |
2020-04-30 | n/a | -6.77 | -1.18p | -6.7 | 0.0 | n/a | n/a | 0.0% |
2021-04-30 | n/a | -16.81 | -2.28p | -9.6 | 0.0 | n/a | n/a | 0.0% |
Scancell developing 'promising' new cancer treatment approach Sharecast News | 23 Jun |
---|---|
Scancell updates protocol for UK trial in melanoma patients Sharecast News | 15 Jun |
Scancell opens recruitment for cancer therapy trial Sharecast News | 11 Apr |
Scancell to produce TCB antibodies | 23-Jun-22 07:00 |
---|---|
Second Price Monitoring Extn | 15-Jun-22 14:08 |
Price Monitoring Extension | 15-Jun-22 14:02 |
Phase 2 SCOPE trial of SCIB1 vaccine expanded | 15-Jun-22 07:59 |
First patient dosed in Modi-1 Phase 1 trial | 13-Jun-22 07:01 |